Lynn Stockwell - Jan 29, 2025 Form 4 Insider Report for Drugs Made In America Acquisition Corp. (DMAA)

Role
CEO and Executive COB, Director, 10%+ Owner
Signature
/s/ Lynn Stockwell
Stock symbol
DMAA
Transactions as of
Jan 29, 2025
Transactions value $
$0
Form type
4
Date filed
2/4/2025, 07:40 PM
Previous filing
Jan 10, 2025
Next filing
Feb 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMAA Ordinary shares Purchase +400K 10.3K Jan 29, 2025 See footnote F1
transaction DMAA Ordinary shares Other -400K -3.9% 9.86M Jan 29, 2025 See footnote F1, F2
transaction DMAA Ordinary shares Sale -5.7M -57.81% 4.16M Jan 29, 2025 See footnote F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAA Rights to receive ordinary shares Purchase +400K 400K Jan 29, 2025 Ordinary shares 400K See footnote F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the 400,000 private units owned by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
F2 As of the Transaction Date, the sponsor transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
F3 As of the Transaction Date, pursuant to share transfer agreements, the sponsor transferred an aggregate of 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share.
F4 The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.